Ambrisentan reduces pulmonary arterial hypertension but does not stimulate alveolar and vascular development in neonatal rats with hyperoxic lung injury

Author(s):
Wagenaar, G.T.M.; Laghmani, E.; Visser, Y.P. de; Sengers, R.M.A.; Steendijk, P.; Baelde, H.J.; Walther, F.J.
Published
2013
Publication type
Article / Letter to editor
pulmonary arterial hypertensionbronchopulmonary dysplasiaendothelin receptor A antagonistnitric oxide synthase inhibitionright ventricular hypertrophy
Date issued
2013-02-28
Language
English
Is part of
AJP - Lung Cellular and Molecular Physiology (2013), Vol. 304, no. 4, p. L264-L275
hdl
1887/104512
doi
10.1152/ajplung.00073.2012